3P CHONGTRAKUL,N SUMPRADIT.ISafE and the evidencebased approach for essential medicines selection in Thailand[J].ESSENTIAL DRUGS MONITOR,2005,34:18-19.
4Downs JR,C learfieldM,Weis S,Whitney E,Shapiro DR,BeerePA,LangendofferA,Stein EA,KruyerW,Gotto AM Jr.Prmiary Prevention of Acute Coronary Events with Lovastatin inMen and Women With Average Cholesterol Levels.Results of AFCAPS/Tex-CAPS[J] JAMA,1998,279(5):1615-1622.
5Kong SX,Crawford SY,Gandhi SK,Seeger JD,Schumock GT,Lam NP,Stubbings J,SchoenMD.Efficacy of 3-hydroxy-3-methyl-glutary coenzyme a reductase inhibitors in the treatment of patientswith hypercholesterolemia:a meta-analysis of clinical trials[J].ClinTher,1997,19(4):778-797.
6John Kjekshus,Terje R,Pedersen.R educing the Risk of Coronary Events:Evidence from the Scandinavian Smi vastain Survival Study(4S)[J].Am JCardiol,1995,76(9):64C-68C.
7Heart Protection Study Collaborative Group.MRC/BHF Heart pro-tection Study of antioxidant vitam in supplementation in 20536 high-risk individuals:a random ized placebo-controlled trial[J].Lancet,2002,360(7):7-22.
8FrickMH,EIo O,HaapaK,Heinonen OP,Heinsaral iP,Helo P,I-luttunen JK,Kaitaniem iP,Koskinen P,M aaninen V,et a.l HelsinkiHeartStndy:prmi ary-prevention trialwith gemfibrozil into iddle-agedmen with dyslipidem ia.Safety of treatmen,t changes in risk fac-tors,and incidence of coronary heart disease[J].N Engl JMed,1987,317 (20):1237-1245.
9SteinerG,StewartD,Hosking JD.Effect of fenofibrate on progres-sion of coronary-artery disease in type 2 diabetes:the Diabetes Athero-sclerosis Intervention Study,a random ised study[J].Lancet.2001,357(9260):905-910.
10Serruys PW,De Feyter PJ,Benghozi R,Hugenholtz PG,LesaffreE.The Lescol (R) Intervention Prevention Study (LIPS):a double-blind,placebo-controlled,randomized trial of the longterm effects of fluvastatin after successful transcatheter therapy in patientswith coronary heartdisease[J].Int J Cardiovasc Intervent,2001,4(4):165-172.
